Skip to main content

Advertisement

SpringerLink
Log in

Genomics of renal cell cancer — Does it provide breakthrough?

  • Review
  • Published:
Pathology & Oncology Research

Abstract

It is a strong hope that the more we characterize the pathways in an individual tumor, the better we will be able to evaluate the response to a specific therapy. Different array technologies could be powerful tools to achieve this goal, i.e. selecting patients on the basis of the genomic and/or proteomic profiles who would really benefit from the target-designed therapy. Genomic analysis of RCC accumulated ample of data which now can be exploited in clinical management of a previously almost uncontrollable disease. Beside the previously identified genetic abnormalities (VHL, MET, EGFR), CAIX seems to be a novel molecular marker of RCC. Array studies also outlined a small set of tumor markers, vimentin, galectin-3, CD74 and parvalbumin, which can define the individual histologic subtypes of RCC. We are at the beginning to take advantage of the genomic results. Some new approaches will interfere with the progression of RCC (anti-VEGF, anti-VEGFR or anti-EGFR therapies). Further novel molecular targets are available, such as HIF, HSP90 or the IFN-regulated genes, which can be used to the fine-tuning of RCC therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benters AJ, Peelen WP, Debruyne FM, Schalken JA: HLAclass-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 48: 709–716, 1991

    Article  Google Scholar 

  2. Boer JM, Huber WK, Sültmann H, et al: Identification and classification on differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-eiement cDNA array. Genome Res 11:1861–1870, 2001

    PubMed  CAS  Google Scholar 

  3. Bromwich E, McMillan DC, Lamb GW, et al: The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91:1236–1238, 2004

    Article  PubMed  CAS  Google Scholar 

  4. Bromwich EJ, McArdle PA, Canna K, et al: The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89:1906–1908, 2003

    Article  PubMed  CAS  Google Scholar 

  5. Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802–811, 2003

    PubMed  CAS  Google Scholar 

  6. Bui MH, Visapaa H, Seligson D, et al: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171:2461–2466, 2004

    Article  PubMed  Google Scholar 

  7. Campbell L, Gumbleton M, Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89:1909–1913, 2003

    Article  PubMed  CAS  Google Scholar 

  8. Castillo M, Petit A, Mellado B, et al: C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 171:2176–2180, 2004

    Article  PubMed  CAS  Google Scholar 

  9. Chautard D, Dalifard I, Chassevent A, et al: Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urol 63:1055–1060, 2004

    Article  PubMed  Google Scholar 

  10. Dancey JE: Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol 22: 2975–2977, 2004

    Article  PubMed  CAS  Google Scholar 

  11. Dawson NA, Guo C, Zak R, et al: A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10: 7812–7819, 2004

    Article  PubMed  CAS  Google Scholar 

  12. Donskov F, Bennedsgarrd KM, Hokland M, et al: Leukocyte orchestration in blood and tumour tissue following interlukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53: 729–739, 2004

    Article  PubMed  CAS  Google Scholar 

  13. Foon KA, Yand XD, Wiener LM, et al: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58: 984–990, 2004

    PubMed  CAS  Google Scholar 

  14. Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 4: 167–174, 2005

    Article  PubMed  CAS  Google Scholar 

  15. Jacobsen J, Grankvist K, Rasmuson T, et al: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297–302, 2004

    Article  PubMed  CAS  Google Scholar 

  16. Jermann M., Stahel RA, Salzberg M, et al: A phase II, openlabel study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57: 533–539, 2006

    Article  PubMed  CAS  Google Scholar 

  17. Joo HJ, Oh DK, Kim YS, et al: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 93:291–296, 2004

    Article  PubMed  CAS  Google Scholar 

  18. Kawata N, Yagasaki H, Hirakata H, et al: The impact of angiogenesis on the prognosis of advanced renal cell carcinoma. Hinyokika Kiyo 50:157–163, 2004

    PubMed  Google Scholar 

  19. Kim, HL, Seligson D, Liu X, et al: Using protein expression to predict survival in clear ceil renal carcinoma. Clin Canc Res 10: 5464–5471, 2004

    Article  CAS  Google Scholar 

  20. Kovacs G: Molecular differential pathology of renal tumors. Histopathology 22: 1–8, 1993

    Article  PubMed  CAS  Google Scholar 

  21. Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumors. J Pathol 183: 131–133, 1997

    Article  PubMed  CAS  Google Scholar 

  22. Lam JS, Belldegrun AS, Figlin RA: Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 10: 6304s-6309s, 2004

    Article  PubMed  CAS  Google Scholar 

  23. Langner C, Ratschek M, Rehak P, et al: Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 171:611–614, 2004.

    Article  PubMed  CAS  Google Scholar 

  24. Langner C, Ratschek M, Rehak P, et al: Are heterogenous results of EGFR immunoreactivity in renal carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 57:773–775, 2004

    Article  PubMed  CAS  Google Scholar 

  25. Lee S-W, Lee K-I, Kim JY: Revealing urologic diseases by proteomic technique. J Chromatogr B Analyt Technol Biomed Life Sci 815: 203–213, 2005

    Article  PubMed  CAS  Google Scholar 

  26. Linehan WM, Vasselli J, Srinivasan R, et al: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10, 6282s-6289s, 2004

    Article  PubMed  CAS  Google Scholar 

  27. Liou LS, Shi T, Duan Z-H, et al: Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol 4:1–11, 2004

    Article  Google Scholar 

  28. Lőrincz T, Tímár J, Szendrői M: Alterations of microvascular density in bone metastases of adenocarcinoma. Pathol Oncol Res 10: 149–153, 2004

    PubMed  Google Scholar 

  29. Mekhail TM, Kawanishi-Tabata R, Tubbs R, et al: Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. Urol Oncol 21:424–430, 2003

    PubMed  CAS  Google Scholar 

  30. Moch H, Sauter G, Buchholz N, et al: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28: 1255–1259, 1997

    Article  PubMed  CAS  Google Scholar 

  31. Moch H: Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation? Pathology 36: 51–57, 2004

    Article  PubMed  CAS  Google Scholar 

  32. Motzer RJ, Michaelson D, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24, 2006

    Article  PubMed  CAS  Google Scholar 

  33. Negrier S, Perol D, Menetier-Caux C, et al: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d’Immunothérapie. J Clin Oncol 22:2371–2378, 2004

    Article  PubMed  CAS  Google Scholar 

  34. Padrik P: Prognostic factors of immunotherapy in metastatic renal ceil carcinoma. Med Oncol 20:325–334, 2003

    Article  PubMed  Google Scholar 

  35. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641–4652, 2003

    PubMed  CAS  Google Scholar 

  36. Paul R, Necknig U, Busch R, et al: Cadherin-6: a new prognostic marker for renal ceil carcinoma. J Urol 171:97–101, 2004

    Article  PubMed  CAS  Google Scholar 

  37. Pavlovich CP, Schmidt LS: Searching for the hereditary causes of renal cell carcinoma. Nat Rev Cancer 4: 381–393, 2004

    Article  PubMed  CAS  Google Scholar 

  38. Ramp U, Krieg T, Caliskan E, et al: XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 35:1022–1088, 2004

    Article  PubMed  CAS  Google Scholar 

  39. Richard S, Lidereau R, Giraud S: The growing family of hereditary renal cell carcinoma. Nephrol Dial Transplant 19: 2954–2958, 2004

    Article  PubMed  Google Scholar 

  40. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028–1043, 2005

    Article  PubMed  CAS  Google Scholar 

  41. Rioux-Leclercq N, Delcros JG, Bansard JY, et al: Immunohistochemical analysis of tumor polyamines discriminates highrisk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol 35:1279–1284, 2004

    Article  PubMed  CAS  Google Scholar 

  42. Roemer A, Schwetmann L, Jung M, et al: Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep 11:529–536, 2004

    PubMed  CAS  Google Scholar 

  43. Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90:794–799, 2004

    Article  PubMed  CAS  Google Scholar 

  44. Sakaeda T, Okumura N, Gotoh A, et al: EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res 22: 1757–1761, 2005

    Article  PubMed  CAS  Google Scholar 

  45. Shimazui T, Yoshikawa K, Uemura H, et al: The level of cadheriu-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 101:963–968, 2004

    Article  PubMed  CAS  Google Scholar 

  46. Staehler M, Rohrmann K, Haseke N, et al: Target agents for the treatment of advanced renal cell carcinoma. Curr Drag Targets 6: 835–846, 2005

    Article  CAS  Google Scholar 

  47. Staller P, Sulitkova J, Lisztwan J, et al: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 425: 307–311, 2003

    Article  PubMed  CAS  Google Scholar 

  48. Sufan RI, Jewett MAS, Ohh M: The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287: F1-F6, 2004

    Article  PubMed  CAS  Google Scholar 

  49. Takahashi M, Rhodes DR, Purge KA, et al: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98: 9754–9759, 2001

    Article  PubMed  CAS  Google Scholar 

  50. Tan M-H, Rogers CG, Cooper JT, et al: Gene expression profiling of renal cell carcinoma. Clin Cancer Res 10: 6315s-6321s, 2004

    Article  PubMed  CAS  Google Scholar 

  51. Twine NC, Stover JA, Marshall B, et al: Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63: 6069–6075, 2003

    PubMed  CAS  Google Scholar 

  52. Uhlrnan DL, Nguyen P, Manivel JC, et al: Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1: 913–920, 1995

    Google Scholar 

  53. Vasselli JR, Shih JH, Iyengar SR, et al: Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100: 6958–6963, 2003

    Article  PubMed  CAS  Google Scholar 

  54. Vogelzang NJ: Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol 24: 1–3, 2006

    Article  PubMed  Google Scholar 

  55. Wittnebel S, Jalil A, Thiery J, et al: The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Netw 16: 123–127, 2005

    PubMed  CAS  Google Scholar 

  56. Yildiz E, Gokce G, Kilicarslan H, et al: Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 93:1087–1093, 2004

    Article  PubMed  CAS  Google Scholar 

  57. Zigeuner R, Ratschek M, Rehak P, et al: Value of p53 as a prognostic marker in histologie subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651–655, 2004

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, H-1085, Budapest, Hungary

    László Kopper MD, PhD

  2. Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary

    József Tímár

Authors
  1. László Kopper MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. József Tímár
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to László Kopper MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopper, L., Tímár, J. Genomics of renal cell cancer — Does it provide breakthrough?. Pathol. Oncol. Res. 12, 5–11 (2006). https://doi.org/10.1007/BF02893425

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893425

Key words

Search

Navigation